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THE INFLUENCE OF PROPANOLOL ON 
PORTOSYSTEMIC SHUNTING 
Sarin SK, Groszmann RJ ,  Mosca PG, Rojkind M, 
Stadecker MJ, Bhatnagar R, Reuben A, et al. Pro- 
pranolol ameliorates the development of portal-systemic 
shunting in a chronic murine schistosomiasis model of 
portal hypertension. J Clin Invest 1991;87:1032-1036. 
ABSTRACT 
We investigated the role of early portal hypotensive 
pharmacotherapy in preventing the development of 
portal-systemic shunting in a portal hypertensive 
model of chronic murine schistosomiasis induced by 
infecting C3H mice with 60 cercariae of Schistosoma 
mansoni. Propranolol was administered in drinking 
water to 20 animals for a period of 6 wk at a dose of 10 
mg-kg-ld-', starting at 5 wk of schistosomal in- 
fection. 32 age-matched mice with chronic schisto- 
somal infection served as controls. All animals were 
studied 11 wk after the infection. Compared with 
controls the portal pressure (10.8 2 0.40 mm Hg) was 
signiscantly lower (P < 0.001) in the propranolol- 
treated animals (7.9 2 0.80 mm Hg). Portal-systemic 
shunting was decreased by 79%, from 12.2 * 3.34% in 
controls to 2.5 2 0.99% in the propranolol group 
(P < 0.05). Portal venous inflow was reduced by 38% in 
the propranolol treated animals (2.50 * 0.73 mumin; 
n = 6) compared with controls (4.00 * 0.34 ml/min; 
n = 8; P < 0.05). The worm burden, the granulomatous 
reaction, the collagen content of the liver, and the 
serum bile acid levels were not significantly different 
between the two groups of animals. These results 
demonstrate that in chronic liver disease induced by 
schistosomiasis, the development of portal-systemic 
shunting can be decreased or prevented by the re- 
duction of flow and pressure in the portal system. 
COluMENTS 
Schistosomiasis is the most common cause of chronic 
liver disease in the world, and its major complications 
are portal hypertension and bleeding esophageal varices 
caused by portosystemic shunting. One of the main 
objectives of this elegant study by Sarin et al. was to 
investigate whether a reduction in portal flow and 
pressure induced by propranolol at an early stage in the 
disease process could influence the development of 
portosystemic shunting (PSS). The answer from this 
study was positive, and the earlier the therapy began, 
the greater the reduction associated with this therapy 
(e.g., 5 wk after schistosomal infection was initiated 
[79%1 vs. 7 wk [57%1). In the propranolol-treated group 
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a significant reduction was seen in portal pressure (27%) 
and in portal venous inflow (38%). No correlation was 
seen between either the fall in portal pressure or in 
portal venous inflow and the effect on PSS, leaving the 
authors to surmise that the combination of the two 
might explain the effect on PSS. 
The original concept of propranolol therapy was that 
a combination of a reduction in cardiac output and local 
splanchnic blood flow by P-blockade would result in a 
reduction in portal pressure (1). Cardiac output was not 
measured in this study, so was it reduced? The combi- 
nation of a drop in heart rate and in mean arterial 
pressure (to a much greater extent than that seen in 
patients) suggests it was, but the fact that hepatic 
arterial flow was not decreased in the treated group 
makes one wonder. Furthermore, the mean heart rate 
decreased from 554 to 493 beats/min in the treated 
group, a fall of only 11%. This is surprising because the 
high basal heart rate would suggest that this is a major 
factor in maintaining cardiac outflow. The decrease 
compares with a fall of 30% in rats with portal vein 
stenosis (2) and a recommended decrease of 25% to 
produce a significant fall in portal pressure and portal 
venous inflow in patients (3). Again, these much greater 
decreases in cardiac output were not accompanied by 
comparable decreases in systemic blood pressure in 
patients (7%) (4) compared with nearly 15% in this 
animal model. 
The group from Yale have pioneered the concept from 
their previous animal models (5, 6) that portal venous 
inflow is increased in cirrhosis. However, they do not 
indicate that this is the case in this model. In fact, 
although portal hypertension precedes PSS by approx- 
imately 2 wk, we do not know whether this is associated 
with increased portal venous inflow. Indeed, portal 
venous inflow may be decreased in animal models of 
schistosomiasis (7). 
Nevertheless, propranolol does cause a decrease in 
portal venous inflow in this model. Therefore what is the 
mechanism of the propranolol effect on PSS? The 
temporal studies would indicate an indirect effect by way 
of the prevention of portal hypertension. The lack of 
correlation between PSS and the reduction in portal 
pressure and portal venous inflow may be because both 
factors are important and additive. It may also mean 
that an additional factor exists. This factor might be a 
direct vasoconstrictive ( p,-adrenergic blockade) on the 
shunts themselves. For example, a single oral dose of 
propranolol can cause a decrease in indocyanine green 
clearance, the decrease in clearance being caused by a 
decrease in hepatic extraction of indocyanine green, 
which in turn can be caused by a decreased shunting. 
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Finally, what is the clinical significance of this finding? 
Patients with schistosomiasis tend to come from the 
rural areas of developing countries. If patients at risk of 
bleeding can be found, started on propranolol and have 
the bleeding controlled at least in terms of their heart 
rate, this would constitute an advance. However, with 
limited medical resources, it will be an extremely 
difficult undertaking. 
lapsed, all within the first year of follow-up. The 
remaining 20 patients continued to have no detectable 
Or hepatitis B virus DNA (dot blot) in Serum 
follOw-uP Of to YIP (mean = 4*3 YIP), although 
Of serum ALT. 
Thirteen patients (65%) lost HBsAg between 0.2 and 
of the 20 patients had detectable serum hepatitis 
virus DNA (dot blot), all 7 patients with persistent 
HBsAg had detectable serum hepatitis B virus DNA by 
the polymerase chain reaction. Sequentid testing in 
HBaAg- patients indicated the serum hepatitis B virus 
DNA usually became undetectable by the polymerase 
chain reaction at about the time of loss of HBsAg. Only 
2 of 13 HBaAg- patients had hepatitis B virus DNA 
detectable in serum by the polymerase chain reaction. 
patients had minimal 
(mean = after loss of HBeAg. Although 
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LOSS OF HBsAg AFTER INTERFERON-CY 
TREATMENT CURE OF CHRONIC 
HEPATITIS B VIRUS? 
Korenman J,  Baker B, Waggoirer J,  Everhart JE, 
DiBisceglie AM, Hoofnagle JH. Long-term remission of 
chronic hepatitis B after alpha-interferon therapy. Ann 
Intern Med 1991;114:629-634. 
EDITORS ABSTRACT 
Sixty-four patients with chronic hepatitis B who 
were treated with interferon-a (recombinant IFN-m-2a 
in 9 patients, recombinant IFN-a-2b in 50 patients and 
lymphoblastoid IFN-a-nl in 5 patients) in protocols 
conducted at the Liver Diseases Section of the National 
Institutes of Health between 1984 and 1986 were 
observed with sequential determinations of serum ALT 
levels, HBsAg and serological markers of hepatitis B 
virus replication CHBeAg, hepatitis B virus DNA poly 
merase, hepatitis B virus DNA by blot hybridization 
and hepatitis B virus DNA by polymerase chain reac- 
tion). Among the 64 treated patients, 23 responded to 
interferon treatment with loss of HBeAg and im- 
provement in serum ALT. Three patients (13%) re- 
COMMENTS 
Chronic hepatitis B is a common and usually per- 
sistent infection. The infection has classically been 
divided into two phases, the early replicative phase and 
the later nonreplicative phase (1, 2 ) .  Progressive liver 
injury occurs during the phase of HBV infection when 
active viral replication occurs. This phase is charac- 
terized by the presence of HBeAg and detectable HBV 
DNA in serum by dot blot or soluble hybridization assays 
(3). Cirrhosis evolves at an annual incidence of nearly 6% 
of patients regardless of the histological severity (4). 
However, in those with severe CAH, cirrhosis develops 
in nearly all patients within 5 yr, and survival is 
diminished (4, 5). Spontaneous seroconversion from 
HBeAg to anti-HBe+ occurs at an annual rate of 
approximately 5% to 15% (1). This postseroconversion 
phase of infection is typically characterized by normal- 
ization of liver tests, histological improvement and loss 
of symptoms (6). Although this latter phase has been 
termed the nonreplicative phase of infection because of 
the loss of tissue HBcAg and serum HBV DNA by dot 
blot or soluble hybridization, the article by Korenman 
and colleagues demonstrates that serum HBV DNA 
persists by the more sensitive technique of polymerase 
chain reaction (7). Thus the previous term nonrepli- 
cative should be replaced by the more accurate label low 
replicative or lutent phase (8). Although HBeAg to 
anti-HBe seroconversion is common, clearance of in- 
fection with loss of HBsAg (and serum HBV DNA by the 
polymerase chain reaction) has been reported to be 
unusual, with an annual rate of 1% to 2% (9,101. It has 
been assumed that the persistence of serum HBsAg after 
clearance of other markers of HBV infection reflected 
integration of portions of viral genome. The report of 
Korenman et al. suggests that HBV DNA is actually 
eradicated when HBsAg is lost (7). However, it remains 
to be shown whether a truly nonreplicative phase of 
infection exists or whether occult HBV sequences 
remain in the liver or in extrahepatic sites such as 
peripheral blood mononuclear cells ( 11 1. 
The main goal of antiviral and immunomodulatory 
therapies in patients with chronic hepatitis B has been 
the clearance of markers of the replicative phase of 
infection (HBeAg and serum HBV DNA polymerase or 
